WROBEL Jay E.
No ORCID on file
· 260 papers in corpus
· active 2000-2004
Frequent coauthors
- GRUBB Gary S. 260
- TEGLEY Christopher M. 260
- JONES Todd K. 260
- EDWARDS James P. 260
- ZHI Lin 260
- FENSOME Andrew 221
- ZHANG PUWEN 195
- TEREFENKO Eugene A. 130
- BENDER Reinhold H. W. 65
- ULLRICH John W. 65
2004
This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds which are antagonists of the progesterone receptor having the general structure:wherein Rand Rmay be single substituents…
2004
This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds which are antagonists of the progesterone receptor having the general structure:wherein Rand Rmay be single substituents…
2004
This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds which are antagonists of the progesterone receptor having the general structure:wherein Rand Rmay be single substituents…
2004
This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds which are antagonists of the progesterone receptor having the general structure:wherein Rand Rmay be single substituents…
2004
This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds which are antagonists of the progesterone receptor having the general structure:wherein Rand Rmay be single substituents…
2004
This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds which are antagonists of the progesterone receptor having the general structure:wherein Rand Rmay be single substituents…
2004
This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds which are antagonists of the progesterone receptor having the general structure:wherein Rand Rmay be single substituents…
2004
This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds which are antagonists of the progesterone receptor having the general structure:wherein Rand Rmay be single substituents…
2004
This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds which are antagonists of the progesterone receptor having the general structure:wherein Rand Rmay be single substituents…
2004
This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds which are antagonists of the progesterone receptor having the general structure:wherein Rand Rmay be single substituents…
2004
This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds which are antagonists of the progesterone receptor having the general structure:wherein Rand Rmay be single substituents…
2004
This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds which are antagonists of the progesterone receptor having the general structure:wherein Rand Rmay be single substituents…
2004
This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds which are antagonists of the progesterone receptor having the general structure:wherein Rand Rmay be single substituents…
2004
This invention relates to cyclic combination therapies and regimens utilizing indoline compounds which are antagonists of the progesterone receptor and having the general structure:A is O, S, or NR; B is a bond or CRR;R, to Rare H, C1 to C6…
2004
This invention relates to cyclic combination therapies and regimens utilizing indoline compounds which are antagonists of the progesterone receptor and having the general structure:A is O, S, or NR; B is a bond or CRR;R, to Rare H, C1 to C6…
2004
This invention relates to cyclic combination therapies and regimens utilizing indoline compounds which are antagonists of the progesterone receptor and having the general structure:A is O, S, or NR; B is a bond or CRR;R, to Rare H, C1 to C6…
2004
This invention relates to cyclic combination therapies and regimens utilizing indoline compounds which are antagonists of the progesterone receptor and having the general structure:A is O, S, or NR; B is a bond or CRR;R, to Rare H, C1 to C6…
2004
This invention relates to cyclic combination therapies and regimens utilizing indoline compounds which are antagonists of the progesterone receptor and having the general structure:A is O, S, or NR; B is a bond or CRR;R, to Rare H, C1 to C6…
2004
This invention relates to cyclic combination therapies and regimens utilizing indoline compounds which are antagonists of the progesterone receptor and having the general structure:A is O, S, or NR; B is a bond or CRR;R, to Rare H, C1 to C6…
2004
This invention relates to cyclic combination therapies and regimens utilizing indoline compounds which are antagonists of the progesterone receptor and having the general structure:A is O, S, or NR; B is a bond or CRR;R, to Rare H, C1 to C6…
2004
This invention relates to cyclic combination therapies and regimens utilizing indoline compounds which are antagonists of the progesterone receptor and having the general structure:A is O, S, or NR; B is a bond or CRR;R, to Rare H, C1 to C6…
2004
This invention relates to cyclic combination therapies and regimens utilizing indoline compounds which are antagonists of the progesterone receptor and having the general structure:A is O, S, or NR; B is a bond or CRR;R, to Rare H, C1 to C6…
2004
This invention relates to cyclic combination therapies and regimens utilizing indoline compounds which are antagonists of the progesterone receptor and having the general structure:A is O, S, or NR; B is a bond or CRR;R, to Rare H, C1 to C6…
2004
This invention relates to cyclic combination therapies and regimens utilizing indoline compounds which are antagonists of the progesterone receptor and having the general structure:A is O, S, or NR; B is a bond or CRR;R, to Rare H, C1 to C6…
2004
This invention relates to cyclic combination therapies and regimens utilizing indoline compounds which are antagonists of the progesterone receptor and having the general structure:A is O, S, or NR; B is a bond or CRR;R, to Rare H, C1 to C6…